- Invited speaker presentation
- Open Access
- Published:
PReS13-SPK-1582: Activity and damage - we have to measure them
Pediatric Rheumatology volume 11, Article number: I23 (2013)
"You can't manage what you don't measure."
The world community--led by the IMACS and PRINTO groups--has developed robust core criteria to measure disease activity and damage for Juvenile Dermatomyositis studies. These measures are tremendously useful in clinical practice, and not just for research.
More problematic has been determining clinically meaningful change. The current definitions of change may not be adequate for clinical trials. Problems include mathematical theoretical ones (e.g. using percent [relative] change for non-ratio measures, and trying to calculate continuous scores from ordinal measures), and practical ones (not incorporating patients' subjective assessments properly).
Proper measures have an important place in the clinical care of children with dermatomyositis; we have made a very strong start, but there is still work to do.
"You can't manage what you don't measure."
The world community--led by the IMACS and PRINTO groups--has developed robust core criteria to measure disease activity and damage for Juvenile Dermatomyositis studies. These measures are tremendously useful in clinical practice, and not just for research.
More problematic has been determining clinically meaningful change. The current definitions of change may not be adequate for clinical trials. Problems include mathematical theoretical ones (e.g. using percent [relative] change for non-ratio measures, and trying to calculate continuous scores from ordinal measures), and practical ones (not incorporating patients' subjective assessments properly).
Proper measures have an important place in the clinical care of children with dermatomyositis; we have made a very strong start, but there is still work to do.
Disclosure of interest
None declared.
Author information
Authors and Affiliations
Rights and permissions
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
About this article
Cite this article
Feldman, B. PReS13-SPK-1582: Activity and damage - we have to measure them. Pediatr Rheumatol 11 (Suppl 2), I23 (2013). https://doi.org/10.1186/1546-0096-11-S2-I23
Published:
DOI: https://doi.org/10.1186/1546-0096-11-S2-I23
Keywords
- Public Health
- Clinical Trial
- Clinical Practice
- Clinical Care
- Subjective Assessment